Literature DB >> 16846230

Solution structure and folding characteristics of the C-terminal SH3 domain of c-Crk-II.

Vasant Muralidharan1, Kaushik Dutta, Jaehyun Cho, Miquel Vila-Perello, Daniel P Raleigh, David Cowburn, Tom W Muir.   

Abstract

Crk-II is a signaling adaptor protein that is involved in many cellular processes including apoptosis, proliferation, and differentiation. It has a modular domain architecture consisting of an Src homology 2 domain (SH2) followed by two Src homology 3 (SH3) domains. The structures and ligand-binding properties of the SH2 and the middle SH3 domains are well-characterized. Several studies suggest that the C-terminal SH3 domain plays an important regulatory role in the protein; however, no structural information is available on this domain, and relatively little is known about its binding partners. In the current work, we have solved the solution NMR structure of the C-terminal SH3 domain. The domain adopts the standard SH3 fold comprising a five-stranded beta barrel. In agreement with alignment and modeling studies, the structure indicates that the canonical-binding surface of the SH3 domain is unusually polar and suggests that this domain may not bind typical PXXP ligands or that it may bind them with reduced affinity. Thermodynamic and kinetic studies show that the domain folds in a reversible two-state manner and that the stability of the fold is similar to that observed for other SH3 domains. These studies offer some insight into the likely structural and thermodynamic consequences of point mutations in the cSH3 domain that are known to deregulate Crk-II function. Our results set the stage for a better understanding the role of the cSH3 domain in the context of the full-length protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846230     DOI: 10.1021/bi060590z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Domain cooperativity in multidomain proteins: what can we learn from molecular alignment in anisotropic media?

Authors:  Tairan Yuwen; Carol Beth Post; Nikolai R Skrynnikov
Journal:  J Biomol NMR       Date:  2011-09-27       Impact factor: 2.835

2.  Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.

Authors:  G Sriram; C Reichman; A Tunceroglu; N Kaushal; T Saleh; K Machida; B Mayer; Q Ge; J Li; P Hornbeck; C G Kalodimos; R B Birge
Journal:  Oncogene       Date:  2011-05-23       Impact factor: 9.867

3.  Prolyl isomerization as a molecular memory in the allosteric regulation of the signal adapter protein c-CrkII.

Authors:  Philipp A M Schmidpeter; Franz X Schmid
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

Review 4.  SH3 domains: modules of protein-protein interactions.

Authors:  Natalya Kurochkina; Udayan Guha
Journal:  Biophys Rev       Date:  2012-06-20

Review 5.  Chemoenzymatic Semisynthesis of Proteins.

Authors:  Robert E Thompson; Tom W Muir
Journal:  Chem Rev       Date:  2019-11-27       Impact factor: 60.622

6.  CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.

Authors:  Renjini Ambika Padmanabhan; Lini Nirmala; Megha Murali; Malini Laloraya
Journal:  Mol Endocrinol       Date:  2011-06-23

7.  Roles for crk in cancer metastasis and invasion.

Authors:  Masumi Tsuda; Shinya Tanaka
Journal:  Genes Cancer       Date:  2012-05

8.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

9.  Proline cis-trans isomerization controls autoinhibition of a signaling protein.

Authors:  Paramita Sarkar; Charles Reichman; Tamjeed Saleh; Raymond B Birge; Charalampos G Kalodimos
Journal:  Mol Cell       Date:  2007-02-09       Impact factor: 17.970

10.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.